Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: BioLineRx forms JV with China's I-Bridge

    Israeli company BioLineRx Ltd. (NASDAQ:BLRX; Tel Aviv:BLRX) formed a joint venture with China's I-Bridge Capital. The JV, dubbed iPharma, is designed primarily to develop candidates originating in Israel for the Chinese…

    Published on 8/26/2016
  • COMPANY NEWS: Management tracks

    Vaccine developer Vaxxilon AG (Reinach, Switzerland) named Arne von Bonin CSO. He was CSO at Affiris AG (Vienna, Austria).Shanghai Pharmaceuticals Holding Co. Ltd. (HKSE:02607; Shanghai:601607) said Jie Zhou resigned as…

    Published on 8/26/2016
  • COMPANY NEWS: Study: FIT, colonoscopy more cost effective than Cologuard

    A study comparing two colorectal cancer screening approaches found that a yearly fecal immunochemical test and a colonoscopy every 10 years was "more effective and less costly" compared with stool DNA test Cologuard …

    Published on 8/26/2016
  • COMPANY NEWS: EMA reviewing first Herceptin biosimilar

    Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said EMA accepted for review an MAA for Myl-1401O, their proposed biosimilar of Herceptin trastuzumab, to treat HER2-positive breast and gastric cancers. …

    Published on 8/25/2016
  • COMPANY NEWS: FDA rejects Amgen's Parsabiv

    Amgen Inc. (NASDAQ:AMGN) received an FDA complete response letter for Parsabiv etelcalcetide to treat secondary hyperparathyroidism in hemodialysis-dependent adults with chronic kidney disease. Spokesperson Kristen …

    Published on 8/24/2016
  • COMPANY NEWS: Lee's, Shenogen to develop cancer combo therapy

    Lee's Pharmaceutical Holdings Ltd. (HKSE:0950) and Shenogen Pharma Group Ltd. (Beijing, China) plan to develop a combination therapy in China to treat late-stage cancers. The partners intend to investigate Pexa-Vec …

    Published on 8/24/2016
  • COMPANY NEWS: Management tracks

    Cancer company BeiGene Ltd. (NASDAQ:BGNE) named Amy Peterson CMO of immuno-oncology, replacing interim CMO Eric Hedrick. Peterson was VP of clinical development at Medivation Inc. (NASDAQ:MDVN), which Pfizer Inc. (NYSE:…

    Published on 8/24/2016
  • COMPANY NEWS: NICE backs Eylea for visual impairment due to BRVO

    The U.K.'s NICE issued a final appraisal determination recommending the use of Eylea aflibercept from Bayer AG (Xetra:BAYN) to treat visual impairment in adults caused by macular edema after branch retinal vein …

    Published on 8/24/2016
  • COMPANY NEWS: Pfizer buying AZ's small molecule anti-infectives business

    Pfizer Inc. (NYSE:PFE) is acquiring the small molecule anti-infectives business of AstraZeneca plc (LSE:AZN; NYSE:AZN) for $550 million in cash up front and $175 million due in January 2019. The unit includes approved …

    Published on 8/24/2016
  • COMPANY NEWS: PTAB invalidates two of Teva's Copaxone patents

    In an inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board invalidated all 20 claims in each of two patents covering a thrice-weekly formulation of multiple sclerosis treatment Copaxone …

    Published on 8/24/2016
  • COMPANY NEWS: Australia's PBAC says Enbrel biosimilar can be substituted

    Australia's Pharmaceutical Benefits Advisory Committee (PBAC) has given pharmacists the authority to substitute the biosimilar Brenzys etanercept for its reference product, autoimmune drug Enbrel etanercept.Merck & Co. …

    Published on 8/23/2016
  • COMPANY NEWS: EC approves Truvada for PrEP

    The European Commission approved a label expansion for HIV therapy Truvada emtricitabine/tenofovir disoproxil fumarate from Gilead Sciences Inc. (NASDAQ:GILD) to include pre-exposure prophylaxis. Truvada is approved for…

    Published on 8/22/2016
  • COMPANY NEWS: Editas names Albright CSO

    Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) hired Charles Albright as CSO. He was VP of genetically defined diseases and genomics at Bristol-Myers Squibb Co. (NYSE:BMY).

    Published on 8/22/2016
  • COMPANY NEWS: EMA reviewing Puma's neratinib

    Puma Biotechnology Inc. (NASDAQ:PBYI) said EMA accepted for review an MAA for oral neratinib (PB272) as an extended adjuvant treatment of HER2-positive early stage breast cancer previously treated with Herceptin …

    Published on 8/22/2016
  • COMPANY NEWS: FDA approves Pfizer's Troxyca ER

    FDA approved Troxyca ER oxycodone/naltrexone from Pfizer Inc. (NYSE:PFE) to treat pain severe enough to require daily, around-the-clock long-term opioid treatment and for which alternative treatments are inadequate. It …

    Published on 8/22/2016
  • COMPANY NEWS: China's Greenland in JV to build Bay Area biotech hub

    The Greenland USA subsidiary of China-based Greenland Holdings Corp. Ltd. (Shanghai:600606) announced plans to construct a biotech R&D center in South San Francisco, Calif. A joint venture including Greenland and the …

    Published on 8/18/2016
  • COMPANY NEWS: Management tracks

    Cancer company Symphogen A/S (Copenhagen, Denmark) said CEO Kirsten Drejer is stepping down. The company promoted CFO Martin Olin to CEO, effective Sept. 1. Drejer is to retain her board seat.Longevity company Calico …

    Published on 8/18/2016
  • COMPANY NEWS: NICE again rebuffs Nexavar for HCC

    In newly issued draft guidance, the U.K.'s NICE said Nexavar sorafenib from Bayer AG (Xetra:BAYN) is not cost-effective to treat advanced hepatocellular carcinoma in adults when surgical or locoregional therapies have …

    Published on 8/18/2016
  • COMPANY NEWS: Judge rules Remicade patent is invalid

    A federal judge ruled that U.S. Patent No. 6,284,471 from Johnson & Johnson (NYSE:JNJ), which covers immune drug Remicade infliximab, is invalid. The decision, which J&J plans to appeal, removes an obstacle to …

    Published on 8/17/2016
  • COMPANY NEWS: Management tracks

    Rare disease company Wave Life Sciences Ltd. (NASDAQ:WVE) hired Keith Regnante as CFO. He was VP of finance at Shire plc (LSE:SHP; NASDAQ:SHPG). Infectious disease company Symbiomix Therapeutics LLC (Newark, N.J.) named…

    Published on 8/17/2016
  • COMPANY NEWS: More allegations emerge in CRISPR patent dispute

    In a document filed this week with the U.S. Patent Trial and Appeal Board concerning a patent interference related to CRISPR/Cas9 gene editing IP, the University of California claimed scientists working at the Broad …

    Published on 8/17/2016
  • COMPANY NEWS: NICE now backs Xalkori for first-line NSCLC

    In a final appraisal determination, the U.K.'s NICE now recommends use of Xalkori crizotinib from Pfizer Inc. (NYSE:PFE) for untreated, anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (…

    Published on 8/17/2016
  • COMPANY NEWS: NICE recommends removal of two drugs from CDF

    The U.K.'s NICE issued preliminary draft guidances recommending the removal of two drugs from coverage by the country's Cancer Drugs Fund (CDF) for specific indications.NICE said Afinitor from Novartis AG (NYSE:NVS; SIX…

    Published on 8/17/2016
  • COMPANY NEWS: Agios names Hirsch CFO

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO) hired Andrew Hirsch as CFO, effective Sept. 19. SVP of Finance Glenn Goddard is to leave the cancer and metabolic company at the end of September. Hirsch was president and CEO of…

    Published on 8/16/2016
  • COMPANY NEWS: Sorrento planning pain spinout

    Sorrento Therapeutics Inc. (NASDAQ:SRNE) plans to spin out its Scintilla Pharmaceuticals Inc. subsidiary as an independent company focused on pain management. The separation is due to occur when Scintilla closes its …

    Published on 8/16/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993